ShareSpot

  • Short Bites: What is a Dental Emergency?

    What is a dental emergency? 

    I often get this question from non-dental personnel including case managers, physician assistants, nurses and nurse practitioners. The following is a quick list of questions you...

  • Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission

    In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as prescribed and...

  • Short Bites: Effects of Antiretroviral Therapy (ART) on Oral Lesions

    A recent study that was conducted among 1200 HIV patient of whom 600 each belonged to with ART and without ART and the occurrence of oral candidiasis and oral hairy leukoplakia. This study shows that oral candidiasis and leukoplakia was less among patients on ART as well as a decrease in the...

  • Short Bites: Do I Pre-medicate Patients Based on a High Viral Load and Low CD4 Count?

    The question I most commonly get asked by oral health providers is...

    Do I pre-medicate patients based on a high viral load and low CD4 count?

    There is no supporting data to support the need for routine antibiotic coverage pre or post dental treatment based on the...

  • Short Bites: Xerostomia in Patients Living with HIV

    In the United States, it is estimated that 1.1 million people are living with HIV. Of those, 1 in 7 do not know they are infected.[1] The number of new HIV diagnoses fell 19% from 2005 to 2014.[1] Because HIV testing has remained stable or increased in recent years, this decrease in diagnoses...

  • Short Bites: Periodontal Health in the Era of Antiretroviral Therapy

    The U.S. Department of Health and Human Services currently recommends that every person living with HIV begin antiretroviral therapy (ART) as soon as possible after diagnosis. Increased availability of testing and treatment along with the above guidelines have reduced the number of new HIV...

  • Short Bites: One in Nine American Men are Infected with Oral HPV

    According to a new study published in the Journal Annals of Internal Medicine, one in nine American men is infected with the oral form of the human papillomavirus (HPV). Nationwide, rates of oral HPV infection are 11.5% of men vs. 3.2% women. HPV 16, the most common type of high-risk HPV and...

  • Giving New Life to New Jersey Syringe Access Programs

    I had the honor to help develop the first legal syringe access program (SAP) in Atlantic City, NJ, almost 10 years ago. In 2006, the New Jersey legislature passed the Blood-Borne Disease Harm Reduction Act, which allowed for the establishment of up to six pilot SAPs in NJ; however, approval from...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an...

  • Bictegravir in Initial Therapy

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • Evolving: A Journey in Practice Transformation

    I remember driving to Chicago on my first day as a Midwest AETC Practice Transformation (PT) Coach filled with both excitement and apprehension to participate in a 3-day intensive training titled Building Blocks of High Performing Primary Care. While the concepts of PT were familiar to me after...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment

    Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...

  • CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison

     

    Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive patients (n...

  • CROI 2017: Dolutegravir in 2-Drug Simplification Studies

    In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...

  • Tuesday Morning HIV Discussion Series: South Central AETC collaborates with the University of Texas Southwestern Medical Center

    In February 2016 Elyse Malanowski, MLS, became the Education Coordinator for Parkland Health and Hospital System/North Texas for the South Central AETC (SCAETC). The SCAETC along with the University of Texas Southwestern (UTSW) Medical Center co-host a weekly informational session for clinicians...

  • Journal Articles by AETC-Affiliated Researchers and Faculty--2016

    It's been a busy year for the AETC community, and we are proud to present the following compilation of published studies produced by members of our network during the 2016 calendar year.   Also included is the HRSA/HAB Workforce Survey results published in the AAHIVM HIV Specialist.  AETC-...

  • Join HAB and NQC in the end+disparities Learning Exchange

    The National Quality Center (NQC) and HIV/AIDS Bureau (HAB) are pleased to announce the end+disparities Learning Exchange! Please watch the informational video and share it with your colleagues and social media contacts!

    The 9-month initiative is open to all Ryan White HIV/AIDS Program (...